Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Otsuka Pharmaceutical

  • Ron Newbold, Otsuka America Pharmaceutical, Inc.

Otsuka is among the top 5 pharma companies from Japan, with strong global drug development and commercial capabilities in CNS disorders, kidney diseases and oncology.

Otsuka aspires to be your strong partner in the CNS and renal space. Our antipsychotic franchise around aripiprazoe and brexpiprazole (Abilify, Rexulti) has made us a global leader in mental health. Based on tolvaptan's recent FDA approval for polycycstic kidney disease (Jynarque for ADPKD), we are now aspiring to become a leader in the renal disease space. We are now searching for opportunities to complement our pipeline with innovative therapeutic solutions to clear unmet needs in psychiatric, neurological and renal disorders - regardless of modality (small molecule, biologic, allogeneic cell therapy, gene therapy or digital therapeutics).

  • Date:Monday, February 11
  • Time:1:30 PM - 1:45 PM
  • Room:Hudson/Empire
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance at:http://bit.ly/BIOCEO19question
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Submission ID:23315
  • Goal for Presentation:Solicit investment and licensing opportunities in psychiatry, neurology and kidney diseases
  • Company Website:https://www.otsuka-us.com/research-and-development/therapeutic-areas
  • Company HQ City:Tokyo
  • Company HQ Country:Japan
  • Market Cap:US$ 28 billion
  • Ticker:4578
  • Exchange:TSE
  • CEO/Top Company Official:Tatsuo Higuchi
  • Year Founded:1921
  • Main Therapeutic Focus:CNS/Neurological
  • Lead Product in Development:Rexulti, Abilify MyCite, Abilify Maintena, Samsca, Jynarque
  • Development Phase of Primary Product:Multiple Products in Market
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):0
  • Additional Information/Comments:We are looking for novel and innovative therapeutic approaches, not for marginal improvements such as reformulations, biosimilar or bio-better approaches. We are interested in meeting biotech companies and investors/VCs. We will not entertain solicitations from CROs, CMOs and consultants.
Speakers
Ron Newbold
Otsuka America Pharmaceutical, Inc.
Back